Match each clinical presentation of acute, life-threatening hemorrhage in a patient on antithrombotic therapy with the foundational mechanism of its most appropriate specific reversal agent.
- A 68-year-old man taking dabigatran for atrial fibrillation who presents with a massive gastrointestinal hemorrhage.Binding of the anticoagulant by a humanized monoclonal antibody fragment with exceptionally high affinity.
- A 75-year-old woman taking rivaroxaban for pulmonary embolism who develops an expanding retroperitoneal hematoma.Direct sequestration of the anticoagulant by a recombinant, catalytically inactive decoy receptor protein.
- A 55-year-old man taking warfarin for a mechanical mitral valve who presents with an acute, space-occupying intracerebral hemorrhage.Rapid replenishment of functional coagulation factors II, VII, IX, and X to bypass the inhibited synthesis pathway.
- A 60-year-old woman receiving a continuous unfractionated heparin infusion who becomes hemodynamically unstable from a massive hemothorax.Neutralization via a highly positively charged peptide that forms a stable, inactive salt complex with the anticoagulant molecule.
Answer
Dabigatran matches with monoclonal antibody fragment binding; Rivaroxaban matches with inactive decoy receptor sequestration; Warfarin matches with factor II, VII, IX, and X replenishment; Heparin matches with positively charged peptide neutralization.
Each antithrombotic class utilizes a distinct molecular mechanism, necessitating a highly specific reversal strategy during life-threatening hemorrhage. Dabigatran (a direct thrombin inhibitor) is reversed by idarucizumab, a targeted antibody fragment. Rivaroxaban (a direct factor Xa inhibitor) is sequestered by andexanet alfa, an engineered decoy receptor. Warfarin (a vitamin K antagonist) depletes coagulation factors II, VII, IX, and X, requiring immediate physiological replacement with prothrombin complex concentrate. Unfractionated heparin (an acidic, negatively charged molecule) is neutralized by protamine, a basic, positively charged peptide.
Step-by-Step Solution
Key Concept
Pharmacologic mechanisms of targeted anticoagulant reversal agents